Swiss Breakfast – Q3 2026
Global Pharma, Global Reinsurance and the Future of Switzerland's Too-Big-To-Fail Framework
Join Moody's Ratings analysts for a focused discussion on key credit developments shaping the outlook for global pharmaceutical and reinsurance companies, alongside an update on Switzerland's evolving too-big-to-fail regulatory framework. Through a series of analyst-led presentations and Q&A sessions, attendees will hear perspectives on sector trends, regulatory developments and the factors influencing credit conditions across these important markets.
Key topics will include:
- Global pharma outlook: Key credit considerations and industry developments influencing pharmaceutical companies.
- Global reinsurance outlook: Credit trends and market dynamics affecting the reinsurance sector.
- Switzerland's too-big-to-fail framework: An update on regulatory developments and their implications for the Swiss banking landscape.
- Analyst Q&A: Opportunity to hear further perspectives on outlooks, trends and regulatory developments.
Speakers
Edoardo Calandro
Senior Vice President, Financial Institutions
Moody's Ratings
Benjamin Serra
Senior Vice President, Financial Institutions
Moody's Ratings
Christian Badorff
Vice President, Financial Institutions
Moody's Ratings
Francesco Bozzano
Vice President, Corporate Finance
Moody's Ratings
Tobias Wagner
Executive Director, Corporate Finance Group
Moody’s Ratings
Jonathan Stalmann
Assistant Vice President
Moody's Ratings
Confirm cancellation
An error occurred trying to play the stream. Please reload the page and try again.
Close